<DOC>
	<DOCNO>NCT00397670</DOCNO>
	<brief_summary>The purpose study study safety contraceptive effectiveness BufferGel use contraceptive diaphragm .</brief_summary>
	<brief_title>Open Label Study Safety Contraceptive Efficacy BufferGel® With Diaphragm</brief_title>
	<detailed_description />
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>healthy woman , sexually active , risk pregnancy desire contraception within age range 18 40 year inclusive lowrisk human immunodeficiency virus ( HIV ) sexually transmit disease ( STD ) infection , currently ( ≥4 month ) single sexual partner also lowrisk HIV STD infection expect partner duration study negative urine pregnancy test admission visit normal cyclic menses usual length 24 35 day last 2 month document history least one spontaneous , normal menstrual cycle ( two menses ) since delivery , abortion , discontinue hormonal contraception/hormonal therapy willing accept risk pregnancy willing engage least 4 act heterosexual vaginal intercourse per cycle period approximately seven month willing randomize either study treatment applicable willing fit diaphragm use diaphragm test product act heterosexual vaginal intercourse duration study willing use test product diaphragm primary method contraception course study [ exception emergency contraception pill ( ECPs ) , indicate ] capable use product diaphragm properly agree observe study direction requirement history allergy sensitivity spermicide , product contain N9 , and/or product contain latex history toxic shock syndrome two UTIs past year currently suspect diagnosed UTI vaginitis dipstick urinalysis wet mount , unless treat proof cure document pregnant , suspected pregnancy desire become pregnant course study history infertility condition may lead infertility contraindication pregnancy ( medical condition ) chronic use class D X medication hospitalize pelvic inflammatory disease without subsequent intrauterine pregnancy one sexual partner past 4 month share injection drug needle within past 6 month , suspect , HIV infection diagnose genital herpes simplex virus ( HSV ) , first occurrence ( initial episode ) within 3 month prior screen , clinical evidence HSV exam diagnose STDs ( include trichomonas ) 6 month prior screen visit lactate breastfeed DepoProvera injection 10 month prior screen vaginal cervical abnormality would interfere proper placement retention test product diaphragm In addition , order eligible participate trial , potential subject must state , best knowledge , sexual partner meet follow criterion : infertile treat Chlamydia trachomatis N. gonorrhoeae past 6 month previously diagnose , suspect , HIV infection one sexual partner past 4 month engage homosexual intercourse past 10 year share injection drug needle past 10 year history allergy sensitivity spermicide product contain N9 history allergy sensitivity product contain latex</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2006</verification_date>
</DOC>